Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Apellis

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

The U.S. Food and Drug Administration approved on Monday Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria.

Benzinga

Apellis Dives As Worse-Than-Expected Syfovre Sales Add Fuel To Market Woes

Apellis stock fell Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.

Investors Business Daily

Apellis Stock Hammered After Eye Drug Gets A Third European Rejection

European regulators rejected Apellis Pharmaceuticals' embattled eye drug, Syfovre, and Apellis stock tumbled to a month-low.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Apellis Crashes 17% As It Stares Down A Likely European Rejection

Apellis said Thursday it expects European regulators to reject its eye disease drug, Syfovre. APLS stock tumbled below its 200-day line.

Investors Business Daily

Apellis Soars 30% After Identifying Potential Culprit Behind Eye Drug Safety Woes

Shares of APLS stock rocketed Wednesday after Apellis identified the potential culprit behind inflammation following its drug, Syfovre.

Investors Business Daily

Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin

Astellas Pharma won FDA approval for a rival to Apellis Pharmaceuticals' eye-disease treatment and APLS stock plunged Monday.

Investors Business Daily

Apellis Pharmaceuticals Reports Q2 Earnings Beat, Investigates Retinal Vasculitis Events

Apellis Pharmaceuticals beats Q2 earnings estimates with strong sales of SYFOVRE, but faces investigation into retinal vasculitis events

Zenger

Read news from The Economist, FT, and more,
with one subscription

Apellis Crashes As Safety Issues Outweigh Massive Eye-Drug Sales Beat

Apellis reported better-than-expected Syfovre sales on Monday, but APLS stock crashed as safety issues continue to plague the eye drug.

Investors Business Daily

Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review

The Dow Jones lead the market rally, while Tesla, Netflix and Taiwan Semiconductor hit growth stocks Thursday.

Investors Business Daily

Apellis Pharma Crashes After Safety Report Undercuts Its Newest Eye Drug

Six recipients of Apellis' new eye-disease drug, Syfovre, experienced inflammation in their eyes, and APLS stock crashed Monday.

Investors Business Daily

Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval

Apellis Pharmaceuticals snagged FDA approval for the first-ever geographic atrophy treatment, leading APLS stock to surge Tuesday.

Investors Business Daily

Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment

Apellis Pharmaceuticals said Friday the Food and Drug Administration will review its new eye-disease drug in February, and APLS stock surged.

Investors Business Daily

Apellis Pharma Crashes On Unexpected Delay For Eye Drug, Taking A Key Rival With It

Apellis reported an unexpected delay for its eye-disease treatment, leading APLS stock to crash and taking shares of Iveric with it.

Investors Business Daily

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today

Apellis and Belite Bio were among the worst-performing biotech stocks Monday after presenting test results in two eye diseases.

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Investors Business Daily

Apellis Surges And Breaks Out As FDA Mulls Its Eye-Disease Treatment

The FDA accepted Apellis Pharmaceuticals' application for an eye-disease treatment on Tuesday, leading APLS stock to surge.

Benzinga

Why Apellis Pharmaceuticals Stock Is Falling After Hours

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering of $300 million of its common stock.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing

Apellis said Wednesday it plans to ask the FDA to approve its eye-disease treatment in the second quarter, and APLS stock surged.

Benzinga

Here's Why Apellis Pharmaceuticals Shares Are Rising

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher by 8.6% at $43.49 after the company announced Pegcetacoplan showed continuous and clinically meaningful effects at month 18 in Phase 3 Derby and Oaks studies for geographic atrophy.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.